NEW INVESTMENT: Grove announced a $10 million investment from Volition Capital (“Volition”), a leading growth equity firm that notably was a large investor in Chewy.  Read More

NEW INVESTMENT: Volition Capital Invests $25M in hackajob  Read More

VOLITION NEWS: Volition Capital Named Top 25 Growth Equity Firm  Read More

ANALYSIS: Rule of 40 Index: Year in Review  Read More

VOLITION UPDATE: Volition Capital Announces Closing of Volition Capital Fund V, L.P. with $675M in Capital Commitments  Read More

NEW INVESTMENT: Zenarate AI Coach Transforming How Agents Learn and Perform through AI Simulation Training  Read More

WHY WE INVESTED IN ZENARATE: Why Volition Invested in Zenarate  Read More


John Hogan of TraceLink Discusses Investing in Technology on Enterprise Talk

Businesses Must Not Invest in Tech for Tech’s Sake

interview by Meeta Ramnani

Read the full interview on

Q: The digital supply chain is changing the enterprise landscape unrecognizably. How do you envisage the SCM technologies changing over the next twelve months?

A: The supply chain, particularly the pharmaceutical supply chain, has been surprisingly ‘un-digital’ but it is definitely undergoing a transformation. The more entities we can get to participate on a digital network platform, the more efficient the supply chain will be. With this, certain business processes will be improved, and will become a lot more seamless.

For example, when working through a process like a product recall or suspect product identification, there are many cases where one party is trying to transmit or exchange information back up the supply chain. Currently, the process is quite fragmented and manual. If this process is digitalized, and all parties involved in the recall process are on one network, digital information sharing would allow the process to become much more efficient.

The other factor that is changing is that everything is becoming very personalized. The pharmaceutical industry is evolving – with innovative approaches to treatments like cell and gene therapies and personalized medicines. There is a much stronger need for specific knowledge on how these therapies and medicines travel full circle through the supply chain. Considerations around logistics, and temperature control are critical, as these drugs are life-dependent and expensive, leaving absolutely no room for error. The industry is in a place where there is a need to adapt to seamless information exchange between supply chain partners, and you need a digital network platform for this to happen.

Read more here.